
- Often considered abnormal (NCI)
- Above 4.0 ng/mL, with age adjustments
- USPSTF, ages 55–69
- Individual decision (grade C, 2018)
- USPSTF, 70 and older
- Recommends against routine screening (grade D)
- Before starting TRT
- AUA advises PSA in men over 40
What raises PSA
- Prostate cancer.
- Benign prostatic hyperplasia, the common age-related enlargement of the prostate.
- Prostatitis or a urinary tract infection.
- Recent ejaculation, a prostate biopsy or vigorous exercise such as cycling.
- Testosterone therapy, which can modestly raise PSA in some men.
What lowers it
Finasteride and dutasteride, used for an enlarged prostate and sometimes hair loss, lower PSA. Clinicians use a lower threshold for "abnormal" in men taking them, so always tell the person ordering the test about these medicines, including topical or compounded forms.
Screening: a personal decision
The U.S. Preventive Services Task Force recommends that men 55 to 69 decide about PSA screening individually after weighing benefits and harms with a clinician, and recommends against routine screening at 70 and older. That 2018 recommendation is being updated.
The trade-offs are real. The National Cancer Institute notes that only about 25% of men who have a biopsy because of an elevated PSA are found to have cancer, and screening can detect slow-growing cancers that would never have caused harm, leading to treatment side effects such as urinary, bowel and sexual problems.
PSA and testosterone therapy
Testosterone can stimulate prostate tissue, so prostate safety is checked before and during treatment. The American Urological Association advises measuring PSA in men over 40 before starting testosterone therapy. The Endocrine Society recommends against therapy in men with a PSA above 4 ng/mL or a prostate nodule without further evaluation, and suggests urology referral if PSA rises more than 1.4 ng/mL in the first year or a confirmed value exceeds 4.0 ng/mL.
Getting an accurate result
MedlinePlus advises avoiding ejaculation for about 24 hours before the test, and the NCI notes some men also avoid vigorous exercise like cycling beforehand. If a result is borderline, repeating it, often with free PSA or other tests, is common before any biopsy. Your HealifyMD clinician will include PSA in baseline and follow-up labs when you are on testosterone.
PSA trends over time
A single PSA value is less informative than the pattern. A slow, steady rise over years is common as the prostate enlarges with age, while a sudden jump deserves a closer look. Keeping results from the same lab and noting any new medications, infections or procedures near each test date helps your clinician interpret changes accurately and avoid unnecessary biopsies.
PSA: common questions
What is a normal PSA?
There is no single normal value. Levels above 4.0 ng/mL are often flagged, but clinicians adjust for age, prostate size and medications.
Does a high PSA mean cancer?
No. Many men with a high PSA have an enlarged or inflamed prostate rather than cancer, which is why follow-up testing is needed.
Can a normal PSA miss cancer?
Yes. Some prostate cancers occur with PSA in the normal range, so symptoms and exam findings still matter.
Will TRT raise my PSA?
It may cause a modest rise in some men. Your clinician compares results with your baseline to spot changes that need evaluation.
What is free PSA?
It measures the portion of PSA not bound to proteins in the blood, and may help decide whether a biopsy is needed when total PSA is borderline.
How often should PSA be checked on testosterone?
Guidelines call for checks during the first year and periodically after. Your clinician sets the schedule based on your age and results.
Sources
We cite government agencies, professional societies and peer-reviewed research. See our editorial policy.
- Prostate-Specific Antigen (PSA) TestNational Cancer Institute
- Prostate Cancer: Screening (2018)U.S. Preventive Services Task Force
- Prostate-specific antigen (PSA) testMedlinePlus (U.S. National Library of Medicine)
- Evaluation and Management of Testosterone Deficiency guidelineAmerican Urological Association
- Testosterone Therapy in Men With Hypogonadism: An Endocrine Society Clinical Practice Guideline (2018)Endocrine Society